王俊俊, 汪玲, 余学进, 陈勇. 和厚朴酚及其代谢物在正常及2型糖尿病大鼠体内的药动学与组织分布对比研究J. 药学学报, 2018,53(6): 987-992. doi: 10.16438/j.0513-4870.2018-0011
引用本文: 王俊俊, 汪玲, 余学进, 陈勇. 和厚朴酚及其代谢物在正常及2型糖尿病大鼠体内的药动学与组织分布对比研究J. 药学学报, 2018,53(6): 987-992. doi: 10.16438/j.0513-4870.2018-0011
WANG Jun-jun, WANG Ling, YU Xue-jin, CHEN Yong. Comparison study on the pharmacokinetic and tissue distribution of honokiol and its metabolites between normal and diabetic ratsJ. Acta Pharmaceutica Sinica, 2018,53(6): 987-992. doi: 10.16438/j.0513-4870.2018-0011
Citation: WANG Jun-jun, WANG Ling, YU Xue-jin, CHEN Yong. Comparison study on the pharmacokinetic and tissue distribution of honokiol and its metabolites between normal and diabetic ratsJ. Acta Pharmaceutica Sinica, 2018,53(6): 987-992. doi: 10.16438/j.0513-4870.2018-0011

和厚朴酚及其代谢物在正常及2型糖尿病大鼠体内的药动学与组织分布对比研究

Comparison study on the pharmacokinetic and tissue distribution of honokiol and its metabolites between normal and diabetic rats

  • 摘要: 本文旨在对比研究和厚朴酚在正常及2型糖尿病大鼠体内的药动学及组织分布差异。采用高脂饮食联合低剂量链脲佐菌素的方法造模,灌胃50 mg·kg-1和厚朴酚后,采用HPLC法检测正常及糖尿病大鼠和厚朴酚及代谢产物在血浆及组织中的浓度,计算药代动力学参数。结果表明糖尿病模型组和厚朴酚的AUC0-t (3 004.7±391.4 μg·h L-1)、Cmax (614.7±182.4 μg·L-1)相对于正常对照组AUC0-t (3 827.2±926.9 μg·h·L-1)、Cmax (872.5±233.1 μg·L-1)显著降低(P < 0.05),模型组代谢产物M2的Cmax (2 785.3±756.3 μg·L-1)和AUC0-t (6 830.6±2 660.4 μg·h·L-1)都大于正常对照组(Cmax为1 711.9±1 026.4 μg·L-1,AUC0-t为5 472.9±2 527.2 μg·h·L-1),且Cmax有极显著性差异(P < 0.01)。糖尿病模型组大鼠肝脏、肾脏和脑中和厚朴酚暴露量均高于正常对照组,M1在模型组肝脏中的暴露量高于正常组; M2在模型组肝脏和肾脏中的暴露量高于正常组。说明在糖尿病病理状态下,和厚朴酚及其代谢产物的药动学和组织分布发生了一定改变。

     

    Abstract: This study was designed to compare normal and diabetic rats in the pharmacokinetic and tissue distribution of honokiol and its metabolites. Type 2 diabetic rat model was established using high-fat diet feeding for 6 weeks followed by single intraperitoneal injection of low dose (30 mg·kg-1) strepotozotocin. The concentration of honokiol and its metabolites were determined by high performance liquid chromatography. Pharmacokinetic parameters were calculated using DAS 3.0 software. The Cmax of honokiol in the normal rats and diabetic rats are 872.5 ±233.1 and 614.7 ±182.4 μg·L-1 respectively (P < 0.05), and the AUC are 3 827.2 ±926.9 and 3 004.7 ±391.4 μg·h·L-1 respectively. Meanwhile, AUC0-t and Cmax of the metabolite M2 were significantly increased in diabetic rats. The concentrations of honokiol in liver, kidney and brain in the diabetic model group were higher than those of the normal control group. Meanwhile, the exposure of M1 in liver, M2 in liver and kidney of the model group were higher than that in the normal group. The data suggest that the pharmacokinetics and tissue distribution of honokiol and its metabolites are changed in the pathological state of diabetes.

     

/

返回文章
返回